{"id":21476,"date":"2022-01-13T11:28:28","date_gmt":"2022-01-13T09:28:28","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=21476"},"modified":"2022-01-13T11:29:50","modified_gmt":"2022-01-13T09:29:50","slug":"pirminiai-duomenys-rodo-kad-vakcinos-nuo-covid-19-islieka-veiksmingos-nuo-sunkios-ligos-eigos-ir-hospitalizavimo-kuri-sukelia-omicron-variantas","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/en\/2022\/01\/13\/pirminiai-duomenys-rodo-kad-vakcinos-nuo-covid-19-islieka-veiksmingos-nuo-sunkios-ligos-eigos-ir-hospitalizavimo-kuri-sukelia-omicron-variantas\/","title":{"rendered":"Pirminiai duomenys rodo, kad vakcinos nuo COVID-19 i\u0161lieka veiksmingos nuo sunkios ligos eigos ir hospitalizavimo, kur\u012f sukelia \u201eOmicron\u201c variantas"},"content":{"rendered":"<p><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-21477\" src=\"https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/01\/60052521_303.jpg?resize=700%2C394&#038;ssl=1\" alt=\"\" width=\"700\" height=\"394\" srcset=\"https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/01\/60052521_303.jpg?w=700&amp;ssl=1 700w, https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/01\/60052521_303.jpg?resize=300%2C169&amp;ssl=1 300w, https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/01\/60052521_303.jpg?resize=18%2C10&amp;ssl=1 18w\" sizes=\"auto, (max-width: 700px) 100vw, 700px\" \/>Europos vaist\u0173 agent\u016bra (EVA) toliau stebi naujus duomenis apie vakcin\u0173 nuo COVID-19 ligos veiksmingum\u0105, taip pat ir lig\u0105, kuri\u0105 sukelia \u201eOmicron\u201c variantas, \u0161iuo metu spar\u010diai plintantis visoje ES.<\/p>\n<p>&nbsp;<\/p>\n<p>Nors atrodo, kad \u201eOmicron\u201c atmaina yra labiau u\u017ekre\u010diama nei kiti variantai, Piet\u0173 Afrikos, Jungtin\u0117s Karalyst\u0117s (JK) ir kai kuri\u0173 ES \u0161ali\u0173 tyrimai rodo, kad rizika patekti \u012f ligonin\u0119 u\u017esikr\u0117tus \u201eOmicron\u201c atmaina yra ma\u017eesn\u0117. Remiantis \u0161iais tyrimais, rizika b\u016bti hospitalizuotam \u0161iuo metu siekia nuo tre\u010ddalio iki pus\u0117s deltos varianto rizikos.<\/p>\n<p>Neseniai paskelbt\u0173 tyrim\u0173 rezultatai rodo, kad vakcinos veiksmingumas nuo simptomin\u0117s ligos, kuri\u0105 sukelia \u201eOmicron\u201c atmaina yra ma\u017eesnis nei kit\u0173 variant\u0173 ir laikui b\u0117gant ma\u017e\u0117ja. Tod\u0117l tik\u0117tina, kad daugiau paskiepyt\u0173 \u017emoni\u0173 susirgs d\u0117l \u201eOmicron\u201c atmainos.<\/p>\n<p>Ta\u010diau \u0161ie tyrimai taip pat rodo, kad vakcinacija ir toliau u\u017etikrina auk\u0161to lygio apsaug\u0105 nuo sunkios ligos formos ir galimo hospitalizavimo. Naujausi \u012frodymai, \u012fskaitant realaus pasaulio efektyvumo duomenis, taip pat rodo, kad \u017emon\u0117s, kuriems buvo skirta stiprinan\u010dioji vakcinos doz\u0117, yra geriau apsaugoti nei tie, kurie gavo tik pirmin\u012f vakcinacijos kurs\u0105. Piet\u0173 Afrikos duomenys rodo, kad \u017emon\u0117s, paskiepyti dviem COVID-19 vakcinos doz\u0117mis, turi iki 70% apsaug\u0105 nuo galimo hospitalizavimo; pana\u0161\u016bs duomenys i\u0161 JK rodo, kad nors apsauga suma\u017e\u0117ja pra\u0117jus keliems m\u0117nesiams po vakcinacijos, apsauga nuo galimo hospitalizavimo v\u0117l padid\u0117ja iki 90 % po skiepijimo stiprinan\u010di\u0105ja vakcinos doze.<\/p>\n<p>EVA pabr\u0117\u017eia, kad vakcinacija teb\u0117ra esmin\u0117 kovos su besit\u0119sian\u010dia pandemija dalis. Atsi\u017evelgiant \u012f nacionalini\u0173 institucij\u0173 rekomendacijas, reik\u0117t\u0173 toliau stengtis didinti \u0161iuo metu visai neskiepyt\u0173 arba tik i\u0161 dalies paskiepyt\u0173 asmen\u0173 skiepijim\u0105, taip pat paspartinti stiprinan\u010di\u0173j\u0173 dozi\u0173 skyrim\u0105.<\/p>\n<p>Daugiau informacijos \u017er.\u00a0<a href=\"https:\/\/www.ema.europa.eu\/en\/news\/preliminary-data-indicate-covid-19-vaccines-remain-effective-against-severe-disease-hospitalisation\">\u010dia.<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><em>Valstybin\u0117s vaist\u0173 kontrol\u0117s tarnybos informacija<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Europos vaist\u0173 agent\u016bra (EVA) toliau stebi naujus duomenis apie vakcin\u0173 nuo COVID-19 ligos veiksmingum\u0105, taip pat ir lig\u0105, kuri\u0105 sukelia \u201eOmicron\u201c variantas, \u0161iuo metu spar\u010diai plintantis visoje ES. &nbsp; Nors atrodo, kad \u201eOmicron\u201c atmaina yra labiau u\u017ekre\u010diama nei kiti variantai, Piet\u0173 Afrikos, Jungtin\u0117s Karalyst\u0117s (JK) ir kai kuri\u0173 ES \u0161ali\u0173 tyrimai rodo, kad rizika patekti&hellip;<\/p>","protected":false},"author":15,"featured_media":21477,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[100],"tags":[],"class_list":["post-21476","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-del-covid-19","category-100","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-5Ao","jetpack_featured_media_url":"https:\/\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/01\/60052521_303.jpg","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/21476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/comments?post=21476"}],"version-history":[{"count":3,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/21476\/revisions"}],"predecessor-version":[{"id":21480,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/21476\/revisions\/21480"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media\/21477"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media?parent=21476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/categories?post=21476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/tags?post=21476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}